Still un­der clin­i­cal hold, Ful­crum locks in sea­soned com­mer­cial leader as CEO

Ful­crum Ther­a­peu­tics has re­cruit­ed a new chief ex­ec­u­tive well versed in the mar­ket­ing world amid man­age­ment up­heaval, a full clin­i­cal hold for its sick­le cell pro­gram and a Phase III for a dif­fer­ent rare dis­ease drug.

Alex Sapir, who served as CEO at Re­Vi­ral un­til Pfiz­er bought it last April, will re­place Robert Gould as Ful­crum CEO on Ju­ly 1. But that’s not the on­ly change hap­pen­ing at the top: In its quar­ter­ly re­port, Ful­crum al­so re­vealed that CFO Es­ther Ra­javelu has re­signed, al­though she will re­main in a con­sult­ing role.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER